Abstract
Background: The treatment of cancer requires scientific advancement. ATP-competitive mTOR inhibitors have been studied as potential antitumor agents.
Objective: A series of substituted benzimidazole compounds were designed, synthesized and characterized via introducing 2-chloroquinolin into 2nd position and most title compounds exhibited enhanced anticancer activities.
Methods: To study the anticancer mechanism, VIa-VIh was successfully docked by iGEMDOCK 2.0 which gives good affinity towards m-TOR/PI3K dual inhibitors. The anti-proliferative activities of these compounds were evaluated on MCF-7 and A549 cell line for Breast and lung cancer, respectively.
Results: 2-(2-chloroquinolin-3-yl)-1H-benzoimidazol-1-yl)(phenyl)methanone (VIa) exhibited significant anti-proliferative activity, especially against breast cancer (IC50 197 μM) for MCF7 cell line and (2-(2- chloroquinolin-3-yl)-1H-benzo[d]imidazol-1-yl)(4-nitrophenyl)methanone (VIc) was significantly active against lung cancer (IC50 89 μM) for A579 cell line.
Conclusion: VIa gives more activity on breast cancer and it gives IC50 197 μM for MCF7 cell line and (2- (2-chloroquinolin-3-yl)-1H-benzo[d]imidazol-1-yl) (4-nitrophenyl) methanone (VIc) lung cancer IC50 89 μM for A579 cell line.
Keywords: Benzimidazole derivatives, molecular modelling, biological evaluation breast cancer, anticancer, 2-chloroquinolin, MCF7 cell line.
Graphical Abstract
[http://dx.doi.org/10.2174/1568009618666181102144934] [PMID: 30387396]
[http://dx.doi.org/10.1016/j.ejmech.2017.02.015] [PMID: 28235701]
[http://dx.doi.org/10.1021/acs.jmedchem.7b00357]
[PMID: 26779371]
[http://dx.doi.org/10.1007/s11523-017-0482-9] [PMID: 28357727]
[http://dx.doi.org/10.1136/esmoopen-2017-000291] [PMID: 29464110]
[http://dx.doi.org/10.1007/s13277-015-3536-6] [PMID: 25990456]
[http://dx.doi.org/10.1038/nature12122] [PMID: 23636326]